FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES

Buket Ergin; Pelin Pelit Arayıcı; Zeynep Mustafaeva; Baxtiyar Mamedov

FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES

Abstract

Cancer is one of the biggest disease of our age. Chance of survival decreases as the diagnosis prolongs. Being an insidious disease makes it harder to determine and diagnose early for cancer. There are lots of studies about fighting this disease. In recent years, vaccine studies have gotten important to prevent cancer. Although cancer vaccine studies have a long history, studies which use peptide vaccines for cancer are applied about last 20 years. Peptide vaccines are created by using peptide sequences which generate the disease as template. The aim is to destroy the tumour antigens by T lymphocytes which are activated by the immune system using peptide sequences.

Keywords

References

[1] Kutluk T., Kars A., (1992) General Information About Cancer, Turkish Cancer Research and War Foundation, Ankara, Turkey.
[2] Çevik O., Aydın U., Gürsoy R.N., (2012) Lymphatic Targeting in Cancer Therapy, Hacettepe University Journal of the Faculty of Pharmacy 32, 1, 67–90.
[3] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D., (2011) Global Cancer Statistics, CA: A Cancer Journal of Clinicans 61, 2, 69-90.
[4] Yılmaz B.E., Health Directorate of Istanbul [Internet] Poole, Haydarpaşa Numune EAH Medical Oncology Unit, Available from: http://istanbulsaglik.gov.tr/w/sb/per/belge/kansere_genel.pdf, [accessed August 25, 2016].
[5] Gürdöl F., Ademoğlu E., (2006) Biochemistry, Nobel Medical Publishing, İstanbul, Turkey.
[6] Kocagöz S., (2014) Technology and Types of Vaccine, Adult Vaccine Symposium (Erişkin aşı sempozyumu), 4 March 2014, İzmir, Turkey.
[7] Anonim, Acıbadem System [Internet] Poole, Available from: http://www.acibadem.com.tr/Hayat/Bilgi/kanserle-savasta-yeni-bir-yontem-immunoterapi [accessed August 27, 2016].
[8] Anonim(2016), Available from: http://www.yesimeralp.com/kanser-ve-immunoterapi [accessed August 27, 2016].

[9] Restifo N.P., Dudley M.E., Rosenberg A.S., (2012) Adoptive Immunotheraphy for Cancer: Harnessing the T Cell Response, İstanbul University Journal of Science 12, 4, 269-81.
[10] Omay SB., (2006) Immunotherapy in Neuro-Oncology, Journal of Turkish Neurosurgery, 16, 1, 23-24.
[11] Wang R.F., Appella E., Kawakami Y., Kang X., Rosenberg S.A., (1996) Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes, J Exp Med 184,6, 2207–2216.
[12] Ladjemi M.Z., Jacot W., Chardes T., Pelegrin A., NavarroTeulon I., (2010) Anti-HER2 Vaccines: New Prospects for Breast Cancer Therapy, Cancer Immunol Immunother 59, 9, 1295-312.
[13] Cohen R.B., (2003) Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal Cancer, Clin Colorectal Cancer 2,4, 246–251.
[14] Shadidi M., Sioud M., (2003) Selective Targeting of Cancer Cells Using Synthetic Peptides, Drug Resist Update 6, 6, 363-71.
[15] Adessi C., Soto C., (2002) Converting a Peptide Into a Drug: Strategies to Improve Stability and Bioavailability, Curr Med Chem 9, 9, 963-78.
[16] Sesardic D. J, (1993) Synthetic Peptide Vaccines, J. Med. Microbiol 39, 241-242.
[17] Bijker M.S., Melief C.J., Offringa R., van der Burg S.H., (2007) Design and Development of Synthetic Peptide Vaccines: Past, Present and Future. Expert Rev. Vaccines 6, 4, 591-603.
[18] Alving C.R., Baylor N.W., Bostrom A., Candries B., Ellenberg S.S., Evans G., Fauci A.S., Foulkes M.A., Folkers G.K., Hilleman M.R., Jordan W., Liu M.A., McVittie L.D., Milstien J, O’Hagan D., Plotkin S.A., Ulmer J.B., Vogel F.R., (2002) The Jordan Report 20th Anniversary Accelerated Development of Vaccines, 39-43(261).
[19] Ben-Yedidia T., Arnon R., (1997) Design of Peptide and Polypeptide Vaccines, Curr. Opin. Biotechnol 8, 4, 442-448.
[20] Diker K.S., (1998) Types of Vaccine, Medisan Publisher 37, 27, 273-278.
[21] Anonim, Buzzle [Internet] Poole, Available from: http://www.buzzle.com/articles/strategies-for-cancer-vaccine-development.html [accessed August 27, 2016].
[22] Anonim, Uzman Veteriner System [Internet] Poole, Available from: http://www.uzmanveteriner.com.tr/veterinerdersnotlari/A%C5%9EILAR.pdf [accessed August 27, 2016].
[23] Yeşilada A., Özkanlı F., (2004) Recent Advances Towards The Rational Design of Peptide Drugs, J. Fac. Pharm, Ankara 33, 3, 157 – 181.
[24] Moisa A.A., Kolesanova E.F., (2012) Synthetic Peptide Vaccines, Article in Biochemistry (Moscow) Supplement Series B Biomedical Chemistry 11, 221-228.
[25] Acar S., (2006) Peptide Protein Covalent Conjugation, PhD Thesis, Faculty of Chemistry-Metallurgical, Yıldız Technical University, İstanbul, Turkey.
[26] Rogers H.W., Weinstock M.A., Harris A.R., (2010) Incidence Estimate of Nonmelanoma Skin Cancer in the United States, Arch Dermatol. 146, 3, 283-7.
[27] Bickers D.R., Lim H.W., Margolis D., (2006) American Academy of Dermatology Association; Society for Investigative Dermatology. The Burden of Skin Diseases: 2004 a Joint Project of the American Academy of Dermatology Association and the Society for Investigative Dermatology, J Am Acad Dermatol 55, 3, 490-500.
[28] Kızılbey K., Mustafaeva Z., (2013) Melanoma Cancer, Journal of Engineering and Naturel Sciences, Sigma 31, 555-559.
[29] Cormier J.N., Salgaller M.L.,Prevette T., Barracchini K.C., Rivoltini L, Restifo N.P., Rosenberg S.A., Marincola F.M., (1997) Enhancement of Cellular Immunity in Melanoma Patients Immunized with a Peptide from MART-1/Melan A, Cancer J Sci Am. 3, 1, 37–44.
[30] Kızılbey K., (2012) Conjugation of Melanoma Based Synthetic Peptides with Polyacrylic Acid and Their Copolymers, Doctoral Thesis, Faculty of Chemistry-Metallurgical, Yıldız Technical University, İstanbul, Turkey.
[31] Rees G., (2005) Understanding Cancer, Morpa Culture Foundation, İstanbul, Turkey.
[32] Kaya S., (2002) Diseases of Larynx, Scientific Medicine Publishing House, Ankara, Turkey.
[33] Schuler P.J., Harasymczuk M., Visus C., DeLeo A., Trivedi S., Lei Y., Argiris A., Butterfield W.G.L.H., Whiteside T.L., Ferris R.L., (2014) Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer, Clin Cancer Res 20, 9, 2433–44.
[34] Albrethsen J., Møller C.H., Olsen J., Raskov H., Gammeltoft S., (2006) Human Neutrophil Peptides 1, 2 and 3 are Biochemical Markers for Metastatic Colorectal Cancer, European Journal of Cancer 42, 17, 3057–3064.
[35] Bloch M., Y. Kam Y., Yavin E., (2012) The Relative Roles of Charge and a Recognition Peptide in Luminal Targeting of Colorectal Cancer by Fluorescent Polyacrylamide, European Journal of Pharmaceutical Sciences 47, 5, 904–913.
[36] Inoda S., Morita R., Hirohashi Y., (2011) The Feasibility of Cep55/c10orf3 Derived Peptide Vaccine Therapy for Colorectal Carcinoma, Experimental and Molecular Pathology 90, 1, 55–60.
[37] Hazama S, Nakamura Y., Takenouchi H., (2014) A Phase I Study of Combination Vaccine Treatment of Five Therapeutic Epitopepeptides for Metastatic Colorectal Cancer; Safety, Immunological Response and Clinical Outcome, Journal of Translational Medicine 10, 12, 63.
[38] Zhang Y., Chen J., Zhang Y., Hu Z., Hu D., Pan Y., Ou S., Lıu G., Yın X, Zhao J., Ren L., Wang J., (2007) Panning and Identification of a Colon Tumor Binding Peptide from a Phage Display Peptide Library, J Biomol Screen OnlineFirst, 12, 3, 429-35.
[39] Arap W., Pasqualini R., Ruoslahti E., (1998) Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science 279, 5349, 377-380.
[40] Topuz E., Aydıner A., Dinçer M., (2003) Breast Cancer, Nobel Medicine Publisher, İstanbul, Turkey.
[41] Peoples G.E., Goedegebuure P.S., Smıth R., Lınehan D.C., Yoshıno I., Eberleın T.J., (1995) Breast and Ovarian Cancer-specific Cytotoxic T Lymphocytes Recognize the Same HER2/neu-derived Peptide, Proc. Natl. Acad. Sci. USA 92, 2, 432-436.
[42] Derman S., Mustafaeva Z., (2015) Particle Size and Zeta Potential Investigation of Synthetic Peptide-Protein Conjugates, Turkish Journal of Biochemistry 4, 4, 282-289.
[43] Özdemir Z.Ö., Mustafaeva Z., (2011) Development of Polyelectrolyte Based Bioconjugates Using with Synthetic Viral Peptides, Journal of Engineering and Natural Sciences, Sigma 29, 65-89.
[44] Derman S., Kızılbey K., Mansuroğlu B., Mustafaeva Z., (2014) Synthesis and Characterization of Canine Parvovirus(CPV) VP2W-7L-20 Synthetic Peptide for Synthetic Vaccine, Fresenius Environmental Bulletin 23, 558-566.
[45] Derman, S., Mustafaeva, Z., Abamor, S. E., Bagırova, M., Allahverdiyev, A., (2015) Preparation, Characterization and Immunological Evaluation: Canine Porvovirus Synthetic Peptide Loaded PLGA Nanoparticles’’, Journal of Biomedical Science, 22, 89, 1-12.

Details

Primary Language

English

Subjects

-

Journal Section

Research Article

Authors

Buket Ergin This is me
Türkiye

Pelin Pelit Arayıcı This is me
Türkiye

Zeynep Mustafaeva This is me
Türkiye

Baxtiyar Mamedov This is me
Azerbaijan

Publication Date

June 1, 2017

Submission Date

September 21, 2016

Acceptance Date

February 8, 2017

Published in Issue

Year 2017 Volume: 35 Number: 2

IZ

https://izlik.org/JA57GT58EG

Cite

RIS / Bibtex

APA

Ergin, B., Pelit Arayıcı, P., Mustafaeva, Z., & Mamedov, B. (2017). FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES. Sigma Journal of Engineering and Natural Sciences, 35(2), 203-211. https://izlik.org/JA57GT58EG

AMA

1.Ergin B, Pelit Arayıcı P, Mustafaeva Z, Mamedov B. FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES. SIGMA. 2017;35(2):203-211. https://izlik.org/JA57GT58EG

Chicago

Ergin, Buket, Pelin Pelit Arayıcı, Zeynep Mustafaeva, and Baxtiyar Mamedov. 2017. “FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES”. Sigma Journal of Engineering and Natural Sciences 35 (2): 203-11. https://izlik.org/JA57GT58EG.

EndNote

Ergin B, Pelit Arayıcı P, Mustafaeva Z, Mamedov B (June 1, 2017) FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES. Sigma Journal of Engineering and Natural Sciences 35 2 203–211.

IEEE

[1]B. Ergin, P. Pelit Arayıcı, Z. Mustafaeva, and B. Mamedov, “FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES”, SIGMA, vol. 35, no. 2, pp. 203–211, June 2017, [Online]. Available: https://izlik.org/JA57GT58EG

ISNAD

Ergin, Buket - Pelit Arayıcı, Pelin - Mustafaeva, Zeynep - Mamedov, Baxtiyar. “FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES”. Sigma Journal of Engineering and Natural Sciences 35/2 (June 1, 2017): 203-211. https://izlik.org/JA57GT58EG.

JAMA

1.Ergin B, Pelit Arayıcı P, Mustafaeva Z, Mamedov B. FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES. SIGMA. 2017;35:203–211.

MLA

Ergin, Buket, et al. “FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES”. Sigma Journal of Engineering and Natural Sciences, vol. 35, no. 2, June 2017, pp. 203-11, https://izlik.org/JA57GT58EG.

Vancouver

1.Buket Ergin, Pelin Pelit Arayıcı, Zeynep Mustafaeva, Baxtiyar Mamedov. FIGHTER MOLECULES AGAINIST TO CANCER – PEPTIDE VACCINES. SIGMA [Internet]. 2017 Jun. 1;35(2):203-11. Available from: https://izlik.org/JA57GT58EG